Science Directed Evolution Teaches Nature the Unnatural, Brings Silicon to Life Published 2 years ago on November 25, 2016 By Giulio Prisco Caltech researchers have achieved a spectacular demonstration that living organisms can be persuaded to make silicon-carbon bonds. The study is the first to show that nature can adapt to incorporate silicon into carbon-based molecules, the building blocks of life. This breakthrough could have en important impact on how medicines and other chemicals are made in the future, and open new horizons to synthetic biology. Carbon-Silicon (Organosilicon) compounds have important applications in pharmaceuticals, agricultural chemicals, paints, semiconductors, computer and TV screens, and other industrial products. These products are made synthetically by chemists in the lab, since silicon-carbon bonds are not found in nature. The Caltech scientists demonstrated that biology can instead be used to manufacture silicon-carbon bonds, in ways that are more environmentally friendly and potentially much less expensive. Lead researcher Frances Arnold, a Caltech Professor of Chemical Engineering, Bioengineering and Biochemistry, said: “We decided to get nature to do what only chemists could do – only better.” Earlier this year, Arnold was awarded the Millennium Technology Prize – the world’s most prominent award for technological innovations that enhance the quality of people’s lives – for her “directed evolution” method, which creates new and better proteins in the laboratory using principles of evolution. The directed evolution technique, used to achieve the new results, enlists the help of nature’s design process – evolution – to come up with better enzymes, which are molecules that catalyze, or facilitate, chemical reactions. “In the same way that breeders mate cats or dogs to bring out desired traits, scientists use directed evolution to create desired enzymes,” noted the Caltech press release about Arnold’s award. The research is published in Science with the title “Directed evolution of cytochrome c for carbon–silicon bond formation: Bringing silicon to life.” A companion review by independent researchers at the Technical University of Berlin, titled “Teaching nature the unnatural,” is also published in Science. The researchers discovered that a protein from a bacterium that grows in hot springs in Iceland, called cytochrome c, which normally shuttles electrons to other proteins, acts like an enzyme to create silicon-carbon bonds. The scientists used directed evolution techniques to mutate the DNA coding for the protein and create an enzyme that can make silicon-carbon bonds 15 times more efficiently than the best catalyst invented by chemists, and with fewer unwanted byproducts. “Silicon is found in nature in many inorganic forms, some of which are constructed by living organisms. Yet, no known biological molecule contains a carbon–silicon (C–Si) bond, and no biological processes to form C–Si bonds have been identified,” note the Berlin reviewers, adding that the beauty and value of the new research lie in the enzyme-promoted formation of an unnatural bond. “This closes a crucial gap between biological and chemical catalysis,” conclude the reviewers. “The impact is unforeseeable, but it seems that we are a big step closer to potentially facilitating industrially relevant reactions such as alkene hydrosilylation with biomolecules.” Toward New Life-Silicon Interfaces and Organosilicon-Based Life Forms? Sek Bik Jennifer Kan, Postdoctoral Scholar in Chemical Engineering Carbon and silicon are chemically very similar. They both can form bonds to four atoms simultaneously, making them well suited to form the long chains of molecules found in life, such as proteins and DNA. However, life as we know it is based on carbon, and no silicon-based forms of life have been found on Earth. “No living organism is known to put silicon-carbon bonds together, even though silicon is so abundant, all around us, in rocks and all over the beach,” says lead author Jennifer Kan, a postdoctoral scholar in Arnold’s lab. The researchers colclude that the in-vitro and in-vivo examples of carbon–silicon bond formation shown in the study, using an enzyme and Earth-abundant iron, “affirm the notion that nature’s protein repertoire is highly evolvable and poised for adaptation.” With only a few mutations, existing proteins can be repurposed to efficiently forge chemical bonds not found in biology and grant access to areas of chemical space that living systems have not explored.” The Caltech breakthrough shows that life can be persuaded to incorporate silicon into its basic components, a research result that could open the way to new synthetic biology-based industrial manufacturing techniques – and perhaps to the possibility to create next-generation interfaces between carbon life and silicon hardware, or even new forms of organosilicon-based life, similar to the artist rendering in the cover image. “This study shows how quickly nature can adapt to new challenges,” added Arnold. “The DNA-encoded catalytic machinery of the cell can rapidly learn to promote new chemical reactions when we provide new reagents and the appropriate incentive in the form of artificial selection. Nature could have done this herself if she cared to.” Images from Lei Chen and Yan Liang/Caltech. Video from Caltech. Important: Never invest (trade with) money you can't afford to comfortably lose. Always do your own research and due diligence before placing a trade. Read our Terms & Conditions here. Trade recommendations and analysis are written by our analysts which might have different opinions. Read my 6 Golden Steps to Financial Freedom here. Best regards, Jonas Borchgrevink. Rate this post: Important for improving the service. Please add a comment in the comment field below explaining what you rated and why you gave it that rate. Failed Trade Recommendations should not be rated as that is considered a failure either way. (0 votes, average: 0.00 out of 5)You need to be a registered member to rate this. Loading... Giulio Prisco Giulio Prisco is a freelance writer specialized in science, technology, business and future studies. Follow @HackedCom Feedback or Requests? Related Topics:CaltechLifeSilicon Up Next Last Week’s Top Cannabis Stock Winners And May’s Stocks To Watch Don't Miss NASA Scientists Sketch Tentative Theory of EmDrive Propulsion You may like Searching for the Meaning of Life in Dubai NASA Curiosity Rover Finds Organic Matter on Mars Altcoins 60 Minutes Showcases Potential of DNA and Genetic Genealogy; Opportunity for Crypto Investors Published 2 weeks ago on October 29, 2018 By Chris Matthews Throughout the years, 60 Minutes has been responsible for reporting on some of the biggest stories in the world. Many of the most memorable episodes have involved world leader interviews, stories on endangered animals, profiles of famous celebrities, and occasionally, segments on promising developments in business and science. A week ago, 60 Minutes had a very interesting report on how the authorities used Genetic genealogy to solve the case of the Golden State Killer, and how the authorities plan to keep using this new field to solve more cold cases in the future. On April 25, 2018, authorities in Sacramento announced that they had solved the notorious case of the Golden State Killer. Authorities were able to use a promising new technique called Genetic genealogy to help identify 72-year-old former police officer, Joseph DeAngelo, as the suspected killer. Genetic Genealogy Genetic genealogy is a mixture of high-tech DNA analysis, high speed computer technology, and family genealogy. The end goal is to determine the level and type of genetic relationship between individuals. In the case of the Golden State Killer, DNA came into play because the killer had committed at least 12 murders, 50 rapes, and many home burglaries. Investigators were able to obtain DNA from the killer at one of the reported crime scenes. After many years of frustrating dead ends, a cold case investigator submitted the obtained DNA sample to GEDmatch. GEDmatch is the largest public genealogy database in the world. After uploading the sample, authorities were able to generate a handful of leads which eventually led to the front doors of Joseph DeAngelo. In addition to the Golden State Killer case, authorities have used Genetic genealogy to make arrests in at least 11 other cold cases. While the science appears to be sound, there is a legal question that has yet to be answered. There is no doubt that attorneys for the accused will raise the question of privacy and whether using databases, thought to be private, should be legal. Opportunity for Crypto Investors While I’ve invested in equities and crypto for many years with varying degrees of success, I’ve never had the opportunity to invest at the beginning of a new frontier. Fortunately, the opportunity has come. Encrypgen (DNA) is a genomic blockchain network that provides customers and partners with best-in-class, next generation, blockchain security for protecting, sharing and re-marketing genomic data. This creates a fair marketplace for a person’s DNA that can be stored private and sold (if a person wishes to do that). Over the past few months, Encrypgen has been gaining attention in the mainstream media because of their revolutionary technology as well as the fact that their closest competition is still years away. In August, Encrypgen released a beta version of its Gene-Chain. The Gene-Chain allows consumers to upload their genetic profile and for researchers to purchase that genetic data. Within the next 2 weeks, the company plans to release the full version of the Gene-Chain which will officially make them a new pioneer in the field of genomic blockchain security. With the DNA token hovering at approximately 5 cents, the time is running out to accumulate at bargain basement prices. I fully expect the token to achieve utility in the next several months which will cause a rocket-like explosion in the token price. There is no looking back now, only forward, and I love what I see. Featured image courtesy of Shutterstock. Important: Never invest (trade with) money you can't afford to comfortably lose. Always do your own research and due diligence before placing a trade. Read our Terms & Conditions here. Trade recommendations and analysis are written by our analysts which might have different opinions. Read my 6 Golden Steps to Financial Freedom here. Best regards, Jonas Borchgrevink. Rate this post: Important for improving the service. Please add a comment in the comment field below explaining what you rated and why you gave it that rate. Failed Trade Recommendations should not be rated as that is considered a failure either way. (1 votes, average: 5.00 out of 5)You need to be a registered member to rate this. Loading... Chris Matthews 5 stars on average, based on 2 rated posts Follow @HackedCom Feedback or Requests? Continue Reading Altcoins Encrypgen Beta Launch Sends Token Soaring Published 3 months ago on August 17, 2018 By Chris Matthews Encrypgen (DNA) provides customers and partners best-in-class, next generation, blockchain security for protecting, sharing and re-marketing genomic data. Although the company has only been around for a few years, it appears to be a major player in the genomic blockchain security space. Security breaches at Ancestry.com and privacy concerns at 23andMe have created a void that Encrypgen hopes to fill. Price Action Earlier this week, Encrypgen reached a significant milestone after launching its Gene-Chain beta platform. DNA token is soaring by 20% since the announcement on Wednesday evening. Encrypgen is far ahead of schedule since the initial expectation was the end of August. The company expects the final live version of the Gene-Chain to be available by the end of September. DNA is a utility token so platform usage will determine its value. DNA is inching its way closer to the finish line and traders appear to be backing it. Since August 1, DNA is one of the best performing ERC20 tokens. I created a list of the top 50 ERC20 tokens and analyzed their returns since August 1. None of them have a positive return. In comparison, DNA has generated a 7% return during the same period. While the return is negligible compared to the fall 2017, it’s still a positive development. Especially since the price rise coincides with a major development milestone. Encrypgen Value Proposition Genetics is playing an increasingly pivotal role in the world of drug discovery. Researchers use genetic data to help them understand how diseases start and how they progress. One of the main reasons that Encrypgen caught my attention is that it is attempting to fill a real world void as a few of the largest non-crypto companies are facing serious issues. Two of those companies are Ancestry.com and 23andMe. Ancestry.com is the most popular genealogical and family tree tracking company. Unfortunately, it appears that popularity comes at a cost. In December, a server on the company’s RootsWeb service exposed a file that has usernames, email addresses and passwords of 300,000 registered users. The stolen information was then leaked and posted online in plain text. Another popular company in the industry, 23andMe, has its own issues regarding privacy. Lawmakers and consumers are expressing concern regarding privacy after a consumer submits their genetic test to the company. This is especially true in light of the recent $300 million collaboration deal that GlaxoSmithKline (GSK) struck with 23andMe. Encrypgen’s Gene-Chain platform appears to be the answer to the problem. Consumers will be able to upload their genetic data via Encrypgen’s secure portal which then goes into the company’s database. That data will then be secured with the company’s Gene-Chain. One of the most interesting parts is that consumers get paid when researchers want to purchase their data. According to a recent article from Reuters, consumers can expect an average payment of $130 each time that researchers buy their data. This is an excellent way for consumers to generate passive income. Conclusion Investors need to keep their eyes on Encrypgen as the company finalizes its Gene-Chain platform. With the recent price action, the coming catalysts, and the compelling value proposition, the DNA token may be one to begin accumulating. Featured image courtesy of Shutterstock. Important: Never invest (trade with) money you can't afford to comfortably lose. Always do your own research and due diligence before placing a trade. Read our Terms & Conditions here. Trade recommendations and analysis are written by our analysts which might have different opinions. Read my 6 Golden Steps to Financial Freedom here. Best regards, Jonas Borchgrevink. Rate this post: Important for improving the service. Please add a comment in the comment field below explaining what you rated and why you gave it that rate. Failed Trade Recommendations should not be rated as that is considered a failure either way. (0 votes, average: 0.00 out of 5)You need to be a registered member to rate this. Loading... Chris Matthews 5 stars on average, based on 2 rated posts Follow @HackedCom Feedback or Requests? Continue Reading Biotech Biotech Dominates July Penny Stock Picks Published 1 year ago on July 17, 2017 By Lester Coleman July brings new opportunities to trade penny stocks, according to the Investopedia top 10 penny stocks to watch. Biotechnology stocks in particular are poised for a breakout. Biotechnology funds broke out of the long-term basing pattern in June, forcing rotational buying pressure, which bodes well for the low-priced sub-sector, with many penny stocks ready to hit multi-year highs. At the same time, the tech sector is getting sold with equal force in a profit-taking exercise that could deliver a period of under-performance for the sector’s lower-priced issues. June’s biotechnology picks drew strong buying interest, led by ImmunoGen, Inc.’s 48% advance to a 52-week high. Small China stocks also posted strength, as China Commercial Credit, Inc. gained close to 35%. China Commercial Credit and June’s three biotech picks return to the July top penny stock list, joined by six new penny stocks. 1. ImmunoGen Inc. (IMGN) Source: Investopedia ImmunoGen, a provider of antibody-drug conjugates (ADCs) for the treatment of cancer, jumped from number four in June to the top spot in July. The stock posted a 12-year high at $20.25 in 2013 and sold off to $5.34 in December 2014. A recovery in 2015 stalled less than a point below the prior peak, creating a decline that continued into an 18-year low at $1.51 in November 2016. Buyers took over in 2017, generating an uptick that reversed at the 2014 resistance approximately three weeks ago. In June, the stock broke out and made the top 10 list for the first time. It could end up in the $8.00 to $10.00 price zone. ImmunoGen creates targeted cancer therapeutics using its proprietary ADC technology. The company’s candidate, mirvetuximab soravtansine, is in a Phase 3 trial for an ovarian cancer, and is in Phase 1b/2 testing in combination regimens for earlier-stage disease. The technology is used in Roche’s Kadcyla, in three other clinical-stage ImmunoGen product candidates, and in programs in development by Amgen, Bayer, Biotest, CytomX, Lilly, Novartis, Sanofi and Takeda. 2. China Commercial Credit, Inc. (CCCR) Source: Investopedia China Commercial Credit Inc. (CCCR), which provides business loans and loan guarantee services to small-to-medium enterprises (SMEs), farmers and individuals in China’s Jiangsu Province, jumped from number five in June to second place in July. The company went public on the U.S. exchanges at $6.50 in August 2013. The stock experienced a downtrend that bottomed out at 25 cents in February 2016 and began an upward trend that stalled at $3.20 in September. The stock hit a higher low in March 2017 before recovering, testing the 2016 high. A breakout should bring broad buying interest that could support a continued upside that could double the price by year’s end. The company was founded in 2008 and provides business loans and loan guarantee services to small-to-medium enterprises, farmers and individuals in China’s Jiangsu Province. 3. CymaBay Therapeutics, Inc. (CBAY) Source: Investopedia CymaBay Therapeutics Inc. (CBAY), a clinical-stage biopharmaceutical company developing therapies to treat specialty and orphan diseases, returns from the June list, where it ranked number 9. The stock rallied to an all-time high at $13.78 in February 2015, then suffered a steep downtrend that continued into the first quarter of 2016. The stock then dropped to an all-time low at 82 cents before bouncing to $3.04 in April, a yearly high, ahead of a pullback that continued into the November low at $1.15. The stock broke above the 2016 high in February 2017, reaching a two-year high at $4.81. Net loss for the 2017 first quarter was $5.4 million, or ($0.20) per diluted share, compared to $6.8 million, or ($0.29) per diluted share in the first quarter of 2016. Net loss in the 2017 first quarter was $1.4 million lower compared to the prior year period, primarily due to the recognition of collaboration revenue in 2017. The rally has now reached a two-year high, attracting buying interest that could move into double digits. 4. Peiris Pharmaceuticals, Inc. (PIRS) Source: Investopedia Pieris Pharmaceuticals Inc., a, clinical-stage biotechnology company committed to providing solutions for oncology, respiratory disease and other therapeutic areas, moved from June’s 7th spot to July’s 4th spot. The stock launched on the OTC market in 2014, trading between $2.00 and $4.25 before falling to $1.26 in January 2016. It ground sideways through November, then tested the first-quarter low ahead of a January 2017 breakaway gap that has drawn steady buying interest. The rally gathered momentum in early May after announcing a partnership with AstraZeneca PLC and is currently testing the 2015 high, the all-time high. The company’s product includes immuno-oncology multi-specifics tailored for the tumor microenvironment, an inhaled Anticalin protein to treat uncontrolled asthma as well as a half-life-optimized Anticalin protein to treat anemia. Anticalin proteins, proprietary to Pieris, are a class of therapeutics validated in the clinic and partnerships with pharmaceutical companies. Anticalin is a registered trademark of Pieris. 5. 22nd Century Group, Inc. (XXII) Source: Investopedia 22nd Century Group, Inc. (XXII), a plant biotechnology company that is a provider of tobacco harm reduction and development of proprietary hemp/cannabis strains, broke out above multi-year resistance near $1.50 in 2013, rallying to a record high a few months later at $6.36. The stock then began a persistent decline through August 2015 before finding support at 56 cents, followed by a bounce to $1.75. The stock has traded within those boundaries for 22-months, bouncing at support three times and reversing at resistance in equal measure. The price returned to that level a fourth time, improving odds for a breakout that could double the price in the year’s second half. 22nd Century Group is a plant biotechnology company focused on genetic engineering and plant breeding that allows the increase or decrease of the level of nicotine in tobacco plants and the level of cannabinoids in cannabis plants. The company’s main goal in tobacco is to reduce the harm caused by smoking. The main goal in cannabis is to develop proprietary hemp/cannabis strains for new medicines and agricultural crops. The stock last month joined the Russell Microcap Index, when FTSE Russell reconstituted its U.S. and global equity indexes. Membership in the Russell Microcap Index means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes. 6. Corindus Vascular Robotics, Inc. (CVRS) Source: Investopedia Corindus Vascular Robotics, Inc. (CVRS), a developer of precision vascular robotics, returned to the national market in 2015 following a trading halt, topping out around $4.50 and starting a decline that continued to reach new lows in January 2017 when it bottomed at around 40 cents. Since that time, the price activity has been constructive, with high volume rally bursts moving the stock into 2016 resistance at $1.75. The bullish behavior has created a cup and handle basing pattern that points to an uptrend into the 2015 high following a breakout. Revenue for the first quarter of 2017 was $0.8 million compared to $1.1 million for the same period in the prior year. The decrease is due mainly to the deferral of system revenue associated with a future obligation to upgrade multiple customer units from the company’s CorPath 200 System to the CorPath GRX System. The company installed three new CorPath Systems in the first quarter of 2017, increasing its total installed base to 48 CorPath Systems. Gross loss was $1.1 million for the 2017 first quarter, compared to a gross profit of $0.03 million for the 2016 first quarter. The cost of revenues for the first 2017 quarter continued to include the effect of under-utilization of production facilities and the cost of CorPath GRX System upgrades that installed pursuant to pre-existing contractual arrangements. The company continues to expect the full year 2017 revenue to be in the range of $13. 7. RADA Electronic Industries, Ltd. (RADA) Source: Investopedia RADA Electronic Industries, Ltd. (RADA), a defense electronics system of advanced electronic systems for airborne and land applications, fell into a multi-decade decline after it joined the Nasdaq in the 1990s. The stock ground out a series of lower highs and lows through January 2016’s all-time 54-cent low. The stock spent 16 months moving sideways in a narrow basing pattern before turning higher in May 2017 and rallying back to 2016 resistance at $1.78. The bullish activity completed a cup and handle breakout pattern that could point to a fast rally into the August 2015 gap between $3.70 and $2.50. Revenues totaled $4.7 million in the 2017 first quarter, up 91% compared to revenues of $2.5 million in the first quarter of 2016. Gross profit totaled $1.7 million in the first 2017 quarter of 2017, a gross margin of 35.7%, compared to gross profit of $6,000 (gross margin of 0.2%) in the 2016 first quarter. Operating income was $0.4 million in the first 2017 quarter compared to an operating loss of $1 million in the 2016 first quarter. Net income attributable to RADA’s shareholders in the 2017 first quarter was $0.4 million, $0.02 per share, versus a net loss of $1.8 million, or $0.23 per share, in the 2016 first quarter. 8. ChromaDex, Corp. (CDXC) Source: Investopedia ChromaDex, Corp. (CDXC), a provider of proprietary health, wellness and nutritional ingredients, that creates science-based solutions to dietary supplement, food and beverage, skin care, sports nutrition and pharmaceutical products, went public in April 2016 at $4.70. The stock rallied to an all-time high at $6.18 in May, then fell one month later to $2.46 in a single session, eventually posting a lower December low. It tested that support level in April 2017, then turned sharply higher, now testing 2017 resistance at $3.80. A breakout could point to a significant upside, taking the stock back to last year’s high. For the first quarter of 2017, ChromaDex reported net sales of $4.4 million, a decrease of 39% compared to the same period of 2016, due mainly to decreased sales in its ingredients business segment, as a result of dropping its largest customer for fiscal year 2016. The ingredients segment created net sales of $2.1 million for Q1 2017, a decline of 55%, compared to the same 2016 period. The net loss attributable to common stock holders for Q1 2017 was $1.9 million or ($0.05) per share versus a net income of $0.3 million or $0.01 per share for Q1 2016. In May, the company announced the closing of the $16.4 million second tranche of the strategic investment of up to $25 million led by Hong Kong business leader Li Ka-shing. Li Ka-shing has invested in many innovative companies in the last decade, including Facebook, Spotify, DeepMind, Siri, Impossible Foods and Modern Meadow. The new investment will support future ChromaDex developments in the global marketplace. The $16.4 million second tranche follows an initial $3.5 million tranche that closed on April 27, 2017. 9. Safe Bulkers, Inc. (SB) Source: Investopedia Safe Bulkers, Inc. (SB), a player in the hot and cold dry bulk shipping sector, topped out at $11.48 in March 2014, then entered a downtrend reaching an all-time low at 30 cents in January 2016. A recovery wave in November stalled at $2.38, followed by sideways action that has completed a small-scale cup and handle breakout pattern. A buying spike over $2.60 can be expected to set the upside into action, supporting a rally that could surpass $5.00. The company declared a cash dividend of $0.50 per share on its 8.00% Series B, Series C and Series D Cumulative Redeemable Perpetual Preferred Shares for the period from April 30, 2017 to July 29, 2017. This is the 16th consecutive cash dividend declared on the company’s Series B Preferred Shares, the 13th cash dividend declared on its Series C Preferred Shares and the 12th cash dividend declared on its Series D Preferred Shares since their respective commencement of trading on the New York Stock Exchange. 10. Ballard Power Systems, Inc. (BLDP) Source: Investopedia Ballard Power Systems, Inc. (BLDP) is a provider of clean energy products that reduce customer costs and risks, and helps customers solve challenges in their fuel cell programs. The stock reached an all-time high at $144.95 in 2000 before falling into a downtrend lasting more than 12 years, sending the stock to an all-time low at 56 cents. A 2013 upward trend continued through 2014, hitting an 8-year high at $8.38, followed by a correction that’s now returned to 2015 resistance at $3.10. A breakout could catch fire, pushing the stock to a test of its 2014 high. Total revenue was $22.7 million in the quarter, an increase of 39% from growth in both power products and technology solutions. Gross margin was 42% in the quarter, an improvement of 22 points due to a shift in product mix toward higher margin technology solutions and heavy duty motive for the China market, including the establishment of a production line in Yunfu, China for the manufacture and assembly of FCvelocity-9SSL fuel cell stacks. Cash operating costs were $10 million in the quarter, a 6% increase due to higher research and product development expenditures as well as a stronger Canadian dollar relative to the U.S. dollar, since a significant amount of cost is denominated in Canadian dollars. Low-priced biotech stocks have risen following a long slumber, with steady buying interest likely to continue. This group should offer a variety of profitable penny stock plays during the quiet summer trading season, while low-priced stocks in other sectors move into narrow trading ranges. Featured image from Shutterstock. Important: Never invest (trade with) money you can't afford to comfortably lose. Always do your own research and due diligence before placing a trade. Read our Terms & Conditions here. Trade recommendations and analysis are written by our analysts which might have different opinions. Read my 6 Golden Steps to Financial Freedom here. Best regards, Jonas Borchgrevink. Rate this post: Important for improving the service. Please add a comment in the comment field below explaining what you rated and why you gave it that rate. Failed Trade Recommendations should not be rated as that is considered a failure either way. (0 votes, average: 0.00 out of 5)You need to be a registered member to rate this. Loading... Lester Coleman 3.9 stars on average, based on 8 rated postsLester Coleman is a veteran business journalist based in the United States. He has covered the payments industry for several years and is available for writing assignments. Follow @HackedCom Feedback or Requests? Continue Reading Ethereum Price Extends Slide as ETH Mining No Long... Update: Crypto Selloff Deepens as Bitcoin Hits New... Etheera (ETA) Hits the Big Time with 82,960% Growt... Monero Price Analysis: XMR/USD Bulls Eyeing Explos... Bitcoin SV Price Briefly Surpasses Bitcoin ABC Ahe... Crypto Update: Selloff Accelerates as Bitcoin Brak... Crypto Market Dumps $7.5 Billion Overnight; Altcoi... Recent Posts Why Investors Should Pay Attention to Decred November 15, 2018 Why Investors Should be Paying Attention to Substratum November 15, 2018 Market Update: U.S. Stocks Plunge; Carnage in Crypto Land November 14, 2018 Cardano Price Analysis: ADA/USDT Smashes Out of Wedge, but Saved by Critical Demand Zone November 14, 2018 Crypto Market Flash-Dips 12%; Bitcoin Price Hits New Yearly Low as ETH, TRX Bleed Out November 14, 2018 Update: Crypto Selloff Deepens as Bitcoin Hits New Yearly Low November 14, 2018 ICO Analysis: CWEX November 14, 2018 Pre-Market Analysis And Chartbook: Markets Flat Ahead of Key Economic Data November 14, 2018 Ethereum Price Extends Slide as ETH Mining No Longer Profitable November 14, 2018 EOS Update: Preparing for a Big Bullish Move November 14, 2018 A part of CCN Hacked.com is Neutral and Unbiased Hacked.com and its team members have pledged to reject any form of advertisement or sponsorships from 3rd parties. We will always be neutral and we strive towards a fully unbiased view on all topics. Whenever an author has a conflicting interest, that should be clearly stated in the post itself with a disclaimer. If you suspect that one of our team members are biased, please notify me immediately at jonas.borchgrevink(at)hacked.com. Trending Cryptocurrencies6 days ago Why Investors Should Pay Attention to Electroneum Cryptocurrencies1 week ago Why Investors Should Pay Attention to Pundi X Altcoins1 week ago John McAfee Gets Skycoin (SKY) Tattoo; Coin Price Immediately Jumps 12% Cryptocurrencies7 days ago Why Investors Should Pay Attention to Ravencoin (RVN) Opinion1 week ago The Ripple Debate Continues as Coinbase Considers Listing XRP Analysis6 days ago Bitcoin Update: Transition from Depression to Disbelief Altcoins1 week ago Tron Gets Five Fiat Pairs Amid 260% Volume Boost; TRX Price Waiting to Move Altcoins1 week ago Litecoin Price Analysis: $60 and Beyond?